{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:22:04Z","timestamp":1790752924234,"version":"4.1.0"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Choroideremia is an incurable, X-linked, recessive retinal dystrophy caused by loss of function mutations in the <jats:italic toggle=\"yes\">CHM<\/jats:italic> gene. It is estimated to affect approximately 1 in 50,000 male patients. It is characterized by progressive degeneration of the retinal pigment epithelium, choroid, and photoreceptors, resulting in visual impairment and blindness. There is an unmet need in choroideremia, because currently, there are no approved treatments available for patients with the disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We review the patient journey, societal impact, and emerging treatments for patients with choroideremia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Its relative rarity and similarities with other retinal diseases in early years mean that diagnosis of choroideremia can often be delayed. Furthermore, its impact on affected individuals, and wider society, is also likely underestimated. AAV2-mediated gene therapy is an investigational treatment that aims to replace the faulty <jats:italic toggle=\"yes\">CHM<\/jats:italic> gene. Early-phase studies reported potentially important visual acuity gains and maintenance of vision in some patients, and a large Phase 3 program is now underway.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Choroideremia is a disease with a significant unmet need. Interventions that can treat progression of the disease and improve visual and functional outcomes have the potential to reduce health care costs and enhance patient quality of life.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000002553","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:07:07Z","timestamp":1556064427000},"page":"2059-2069","source":"Crossref","is-referenced-by-count":44,"title":["CHOROIDEREMIA"],"prefix":"10.1097","volume":"39","author":[{"given":"Mark E.","family":"Pennesi","sequence":"first","affiliation":[{"name":"Casey Eye Institute, Oregon Health & Science University, Portland, Oregon;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Birch","sequence":"additional","affiliation":[{"name":"Retina Foundation of the Southwest, Dallas, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacque L.","family":"Duncan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of California, San Francisco, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bennett","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Perelman School of Medicine, Center for Advanced Retinal and Ocular Therapeutics, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniz","family":"Girach","sequence":"additional","affiliation":[{"name":"Nightstar Therapeutics, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230816","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.trsl.2012.12.007","article-title":"Gene therapy for retinal disease","volume":"161","author":"McClements","year":"2013","journal-title":"Transl Res"},{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ajo.2013.05.009","article-title":"Choroideremia: towards a therapy","volume":"156","author":"Kalatzis","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R3-20230816","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/21678707.2015.1046434","article-title":"Pathogenic mechanisms and the prospect of gene therapy for choroideremia","volume":"3","author":"Dimopoulos","year":"2015","journal-title":"Expert Opin Orphan Drugs"},{"key":"R4-20230816","first-page":"1195","article-title":"Detection and characterization of point mutations in the choroideremia candidate gene by PCR-SSCP analysis and direct DNA sequencing","volume":"50","author":"van den Hurk","year":"1992","journal-title":"Am J Hum Genet"},{"key":"R5-20230816","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00431-008-0740-z","article-title":"Rab proteins and Rab-associated proteins: major actors in the mechanism of protein-trafficking disorders","volume":"167","author":"Corbeel","year":"2008","journal-title":"Eur J Pediatr"},{"key":"R6-20230816","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/13816810.2011.620056","article-title":"Choroideremia: a review of general findings and pathogenesis","volume":"33","author":"Coussa","year":"2012","journal-title":"Ophthalmic Genet"},{"key":"R7-20230816","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1167\/iovs.16-20230","article-title":"The spectrum of CHM gene mutations in choroideremia and their relationship to clinical phenotype","volume":"57","author":"Simunovic","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/13816819509057855","article-title":"Phenotype variations within a choroideremia family lacking the entire CHM gene","volume":"16","author":"Ponjavic","year":"1995","journal-title":"Ophthalmic Genet"},{"key":"R9-20230816","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/mgg3.208","article-title":"Analysis of a large choroideremia dataset does not suggest a preference for inclusion of certain genotypes in future trials of gene therapy","volume":"4","author":"Freund","year":"2016","journal-title":"Mol Genet Genomic Med"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/bjo.86.6.658","article-title":"Retrospective, longitudinal, and cross sectional study of visual acuity impairment in choroideraemia","volume":"86","author":"Roberts","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"R12-20230816","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ophtha.2016.10.022","article-title":"Natural history of the central structural abnormalities in choroideremia: a prospective cross-sectional study","volume":"124","author":"Aleman","year":"2017","journal-title":"Ophthalmology"},{"key":"R13-20230816","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajo.2017.05.002","article-title":"Measurement and reproducibility of preserved ellipsoid zone area and preserved retinal pigment epithelium area in eyes with choroideremia","volume":"179","author":"Hariri","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"e0167526","DOI":"10.1371\/journal.pone.0167526","article-title":"Multimodal imaging of photoreceptor structure in choroideremia","volume":"11","author":"Sun","year":"2016","journal-title":"PLoS One"},{"key":"R15-20230816","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1167\/iovs.13-13454","article-title":"High-resolution adaptive optics retinal imaging of cellular structure in choroideremia","volume":"55","author":"Morgan","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R16-20230816","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1167\/iovs.06-0424","article-title":"Remodeling of the human retina in choroideremia: rab escort protein 1 (REP-1) mutations","volume":"47","author":"Jacobson","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R17-20230816","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0161-6420(00)00643-6","article-title":"Evaluation of retinal photoreceptors and pigment epithelium in a female carrier of choroideremia","volume":"108","author":"Syed","year":"2001","journal-title":"Ophthalmology"},{"key":"R18-20230816","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1001\/archophthalmol.2012.1117","article-title":"Clinical characteristics of a large choroideremia pedigree carrying a novel CHM mutation","volume":"130","author":"Huang","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R19-20230816","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/ajmg.a.32727","article-title":"CHM gene molecular analysis and X-chromosome inactivation pattern determination in two families with choroideremia","volume":"149A","author":"Perez-Cano","year":"2009","journal-title":"Am J Med Genet A"},{"key":"R20-20230816","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0002-9394(86)90832-9","article-title":"Electroretinographic findings in selected pedigrees with choroideremia","volume":"101","author":"Sieving","year":"1986","journal-title":"Am J Ophthalmol"},{"key":"R21-20230816","first-page":"309","article-title":"Genetic and phenotypic characteristics of three Mainland Chinese families with choroideremia","volume":"18","author":"Zhou","year":"2012","journal-title":"Mol Vis"},{"key":"R22-20230816","doi-asserted-by":"crossref","first-page":"2066.e1\u201310","DOI":"10.1016\/j.ophtha.2006.05.045","article-title":"Choroideremia: variability of clinical and electrophysiological characteristics and first report of a negative electroretinogram","volume":"113","author":"Renner","year":"2006","journal-title":"Ophthalmology"},{"key":"R23-20230816","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/eye.2010.157","article-title":"Cystic macular oedema on spectral-domain optical coherence tomography in choroideremia patients without cystic changes on fundus examination","volume":"25","author":"Genead","year":"2011","journal-title":"Eye (Lond)"},{"key":"R24-20230816","doi-asserted-by":"crossref","first-page":"OCT377","DOI":"10.1167\/iovs.15-18421","article-title":"Visual function and central retinal structure in choroideremia","volume":"57","author":"Heon","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R25-20230816","first-page":"3899","article-title":"Natural history of progression of choroideremia (NIGHT) study: cross-sectional analysis of baseline characteristics","volume":"59","author":"Lam","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R26-20230816","first-page":"3898","article-title":"The natural history of the progression of choroideremia (NIGHT) study: longitudinal changes in visual acuity over 12 months","volume":"59","author":"Pennesi","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R27-20230816","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1167\/iovs.17-22486","article-title":"Characterizing the natural history of visual function in choroideremia using microperimetry and multimodal retinal imaging","volume":"58","author":"Jolly","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R28-20230816","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1167\/iovs.15-18362","article-title":"A qualitative and quantitative assessment of fundus autofluorescence patterns in patients with choroideremia","volume":"57","author":"Jolly","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R29-20230816","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0008-4182(03)80047-9","article-title":"Clinical diagnoses that overlap with choroideremia","volume":"38","author":"Lee","year":"2003","journal-title":"Can J Ophthalmol"},{"key":"R30-20230816","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.2147\/OPTH.S65732","article-title":"Recent advances and future prospects in choroideremia","volume":"9","author":"Zinkernagel","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"R31-20230816","first-page":"139","article-title":"Retinal dystrophies, genomic applications in diagnosis and prospects for therapy","volume":"4","author":"Nash","year":"2015","journal-title":"Transl Pediatr"},{"key":"R32-20230816","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/sj.ejhg.5200538","article-title":"NRL S50T mutation and the importance of 'founder effects' in inherited retinal dystrophies","volume":"8","author":"Bessant","year":"2000","journal-title":"Eur J Hum Genet"},{"key":"R33-20230816","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ajo.2004.11.005","article-title":"Cancer-associated nummular loss of the pigment epithelium","volume":"139","author":"Wu","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R35-20230816","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamaophthalmol.2016.2627","article-title":"Public attitudes about eye and vision health","volume":"134","author":"Scott","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"R36-20230816","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ophtha.2013.09.043","article-title":"Association between visual field defects and quality of life in the United States","volume":"121","author":"Qiu","year":"2014","journal-title":"Ophthalmology"},{"key":"R37-20230816","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/cxo.12391","article-title":"Ocular disease and driving","volume":"99","author":"Wood","year":"2016","journal-title":"Clin Exp Optom"},{"key":"R38-20230816","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/jamaophthalmol.2016.2394","article-title":"Association of vision impairment and major eye diseases with mobility and independence in a Chinese population","volume":"134","author":"Fenwick","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"R39-20230816","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.ophtha.2013.01.068","article-title":"The economic burden of vision loss and eye disorders among the United States population younger than 40 years","volume":"120","author":"Wittenborn","year":"2013","journal-title":"Ophthalmology"},{"key":"R40-20230816","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000435886","article-title":"Threshold levels of visual field and acuity loss related to significant decreases in the quality of life and emotional states of patients with retinitis pigmentosa","volume":"54","author":"Azoulay","year":"2015","journal-title":"Ophthalmic Res"},{"key":"R41-20230816","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/eye.2009.176","article-title":"Relationship between peripheral visual field loss and vision-related quality of life in patients with retinitis pigmentosa","volume":"24","author":"Sugawara","year":"2010","journal-title":"Eye (Lond)"},{"key":"R42-20230816","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/bjo.2007.127092","article-title":"Depression and the vision-related quality of life in patients with retinitis pigmentosa","volume":"92","author":"Hahm","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R43-20230816","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/opo.12388","article-title":"The incidence and predictors of depressive and anxiety symptoms in older adults with vision impairment: a longitudinal prospective cohort study","volume":"37","author":"Heesterbeek","year":"2017","journal-title":"Ophthalmic Physiol Opt"},{"key":"R44-20230816","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/aos.12467","article-title":"Socio-economic characteristics of patients with generalized retinal dystrophy in Denmark","volume":"93","author":"Bertelsen","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"R45-20230816","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archophthalmol.2011.2820","article-title":"Health services utilization and cost of retinitis pigmentosa","volume":"130","author":"Frick","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R46-20230816","doi-asserted-by":"crossref","first-page":"e003471","DOI":"10.1136\/bmjopen-2013-003471","article-title":"The economic burden of visual impairment and blindness: a systematic review","volume":"3","author":"K\u00f6berlein","year":"2013","journal-title":"BMJ Open"},{"key":"R47-20230816","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4274\/tjo.41017","article-title":"Recent advancements in gene therapy for hereditary retinal dystrophies","volume":"47","author":"\u00d6ner","year":"2017","journal-title":"Turk J Ophthalmol"},{"key":"R48-20230816","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"R50-20230816","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0042-6989(02)00389-9","article-title":"Gene therapy for choroideremia: in vitro rescue mediated by recombinant adenovirus","volume":"43","author":"Anand","year":"2003","journal-title":"Vis Res"},{"key":"R51-20230816","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00109-013-1006-4","article-title":"Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo","volume":"91","author":"Tolmachova","year":"2013","journal-title":"J Mol Med (Berl)"},{"key":"R52-20230816","doi-asserted-by":"crossref","first-page":"e61396","DOI":"10.1371\/journal.pone.0061396","article-title":"AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models","volume":"8","author":"Vasireddy","year":"2013","journal-title":"PLoS One"},{"key":"R53-20230816","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1056\/NEJMc1509501","article-title":"Visual acuity after retinal gene therapy for choroideremia","volume":"374","author":"Edwards","year":"2016","journal-title":"N Engl J Med"},{"key":"R54-20230816","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fnins.2017.00174","article-title":"Retinal gene therapy: surgical vector delivery in the translation to clinical trials","volume":"11","author":"Ochakovski","year":"2017","journal-title":"Front Neurosci"},{"key":"R55-20230816","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ymthe.2006.03.005","article-title":"Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection","volume":"13","author":"Jacobson","year":"2006","journal-title":"Mol Ther"},{"key":"R56-20230816","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum Gene Ther"},{"key":"R57-20230816","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","article-title":"Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years","volume":"130","author":"Jacobson","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R58-20230816","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1167\/iovs.17-22402","article-title":"Subretinal injection for gene therapy does not cause clinically significant outer nuclear layer thinning in normal primate foveae","volume":"58","author":"Ochakovski","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R61-20230816","first-page":"4485","article-title":"AAV2-hCHM subretinal delivery to the macula in choroideremia: preliminary six month safety results of an ongoing Phase I\/II gene therapy trial [ARVO abstract 4485]","volume":"58","author":"Aleman","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R63-20230816","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.exer.2017.01.001","article-title":"Mechanism and evidence of nonsense suppression therapy for genetic eye disorders","volume":"155","author":"Richardson","year":"2017","journal-title":"Exp Eye Res"},{"key":"R64-20230816","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1093\/hmg\/ddw184","article-title":"Functional rescue of REP1 following treatment with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and the nonsense-mediated zebrafish model","volume":"25","author":"Moosajee","year":"2016","journal-title":"Hum Mol Genet"},{"key":"R65-20230816","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12886-016-0225-1","article-title":"Worldwide Argus II implantation: recommendations to optimize patient outcomes","volume":"16","author":"Ghodasra","year":"2016","journal-title":"BMC Ophthalmol"},{"key":"R66-20230816","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/bjophthalmol-2012-301525","article-title":"The Argus II epiretinal prosthesis system allows letter and word reading and long-term function in patients with profound vision loss","volume":"97","author":"da Cruz","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R67-20230816","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.ophtha.2016.06.049","article-title":"Five-year safety and performance results from the Argus II retinal prosthesis system clinical trial","volume":"123","author":"da Cruz","year":"2016","journal-title":"Ophthalmology"},{"key":"R68-20230816","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/cxo.12444","article-title":"Improvements in vision-related quality of life in blind patients implanted with the Argus II Epiretinal Prosthesis","volume":"100","author":"Duncan","year":"2017","journal-title":"Clin Exp Optom"},{"key":"R69-20230816","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/j.ophtha.2016.06.041","article-title":"Gene therapy and stem cell transplantation in retinal disease: the new frontier","volume":"123","author":"MacLaren","year":"2016","journal-title":"Ophthalmology"},{"key":"R70-20230816","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ophtha.2006.06.049","article-title":"Autologous transplantation of the retinal pigment epithelium and choroid in the treatment of neovascular age-related macular degeneration","volume":"114","author":"MacLaren","year":"2007","journal-title":"Ophthalmology"},{"key":"R71-20230816","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1167\/iovs.04-0118","article-title":"Outcome of transplantation of autologous retinal pigment epithelium in age-related macular degeneration: a prospective trial","volume":"45","author":"Binder","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R72-20230816","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ajo.2011.06.007","article-title":"A free retinal pigment epithelium-choroid graft in patients with exudative age-related macular degeneration: results up to 7 years","volume":"153","author":"van Zeeburg","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R73-20230816","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0140-6736(14)61376-3","article-title":"Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1\/2 studies","volume":"385","author":"Schwartz","year":"2015","journal-title":"Lancet"},{"key":"R74-20230816","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1073\/pnas.1119416110","article-title":"Reversal of end-stage retinal degeneration and restoration of visual function by photoreceptor transplantation","volume":"110","author":"Singh","year":"2013","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:23:57Z","timestamp":1692231837000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002553"}},"subtitle":["Retinal Degeneration With an Unmet Need"],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":69,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002553","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}